{
    "nctId": "NCT00357734",
    "briefTitle": "Iressa Follow-up Trial",
    "officialTitle": "Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.",
    "overallStatus": "COMPLETED",
    "conditions": "Lung Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Number of Serious Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of written informed consent to participate in the trial.\n* Female or male aged 18 years and over.\n* Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation\n\nExclusion Criteria:\n\n* Known severe hypersensitivity to ZD1839\n* Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.\n* Withdrawal from a parent ZD1839 trial because of tumor progress",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}